A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease

About the study

This is a study to evaluate the effect of voxelotor on daily physical activity and sleep
quality, as measured by a wrist-worn device in participants with sickle cell disease (SCD)
and chronic moderate anemia.

Study point of contact

Julia Martinisi
1-650-452-7918
[email protected]
Barbara Moehring, Pharm D
650-351-4738
[email protected]

Locations

10 United States sites

Age

12 to 55 Years

Genotypes

SCA

Phase

Phase 4

Study type

Interventional

Gender

All

Interventions

Drug

Compensation

Unknown

participation requirements

1. Male or female participants with SCA (sickle hemoglobin with two sickle cell genes
[HbSS] or sickle hemoglobin (S) and one beta thalassemia gene [HbS β0] thal genotype)

2. Between 12 to 55 years of age (inclusive)

3. Screening Hb level ≤8.0 g/dL

4. Treatment with hydroxyurea (HU) therapy on study is permitted if the participant has
been on a stable dose for at least 90 days before enrollment with no dose
modifications planned or anticipated by the Investigator

5. Treatment with glutamine is permitted

6. Treatment with erythropoiesis-stimulating agents (ESAs) is permitted if the
participant has been on a stable dose for at least 12 weeks before enrollment with no
dose modifications planned or anticipated by the Investigator

7. Female participants of child-bearing potential must use highly effective methods of
contraception to 30 days after the last dose of study drug. Male participants must use
barrier methods of contraception to 30 days after the last dose of study drug

8. Females of child-bearing potential are required to have a negative pregnancy test
before the administration of study drug

9. Written informed consent and/or parental/guardian consent and participant assent per
Institutional Review Board (IRB) policy and requirements, consistent with ICH
guidelines

participation restrictions

1. Red blood cell (RBC transfusion within 3 months before initiation of study drug

2. Planned initiation of regularly scheduled RBC transfusion therapy (also termed
chronic, prophylactic, or preventive transfusion) during the study

3. Hospitalization for vaso-occlusive crisis (VOC) or acute chest syndrome (ACS) within
30 days prior to informed consent/assent.

4. More than 10 VOCs requiring hospitalization, emergency department or clinic visit
within the past 12 months

5. Planned elective surgery within the next 6 months

6. Physical inactivity attributable to clinically significant musculoskeletal,
cardiovascular, or respiratory comorbidities

7. Anemia due to bone marrow failure (eg, myelodysplasia)

8. Absolute reticulocyte count (ARC) < 100 x10^9/L 9. Screening alanine aminotransferase (ALT) > 4× upper limit of normal (ULN)

10. Severe renal dysfunction (estimated glomerular filtration rate [GFR] < 30 mL/min/1.73 m2 by Schwartz formula) or is on chronic dialysis 11. Known active hepatitis A, B or C or known to be human immunodeficiency virus (HIV)-positive. 12. Females who are breast-feeding or pregnant 13. Major surgery within 8 weeks before enrollment. Participants must have completely recovered from any previous surgery before enrollment 14. History of hematopoietic stem cell transplant or gene therapy 15. Received an investigational drug within 30 days or 5-half-lives, whichever is longer, prior to consent, or is currently participating in another trial of an investigational or marketed drug (or medical device) 16. Use of concomitant medications (eg, crizanlizumab) that confound the ability to interpret data from the study 17. Medical, psychological, or behavioral condition that, in the opinion of the Investigator, would confound or interfere with evaluation of safety and/or efficacy of the study drug, prevent compliance with the study protocol; preclude informed consent; or, render the participant unable/unlikely to comply with the study procedures 18. Use of herbal medications (e.g., St. John's Wort), sensitive cytochrome P450 (CYP) 3A4 substrates with a narrow therapeutic index, strong CYP3A4 inhibitors, fluconazole, or moderate or strong CYP3A4 inducers 19. Symptomatic coronavirus disease of 2019 (COVID-19) infection

Locations

  • Farmington, Connecticut, United States, UConn Health, 06030 [Recruiting]
  • Atlanta, Georgia, United States, Children's Healthcare of Atlanta, 30342 [Recruiting]
  • Detroit, Michigan, United States, Children's Hospital of Michigan, 48201 [Not yet recruiting]
  • Bronx, New York, United States, The Children's Hospital at Montefiore, 10476 [Recruiting]
  • New York, New York, United States, Icahn School of Medicine at Mount Sinai, 10029 [Not yet recruiting]
  • Durham, North Carolina, United States, Duke Department of Pediatrics, 27710 [Recruiting]
  • Columbus, Ohio, United States, The Ohio State University Wexner Medical Center, 43210 [Recruiting]
  • Pittsburgh, Pennsylvania, United States, University of Pittsburgh Medical Center, 15213 [Recruiting]
  • Houston, Texas, United States, The University of Texas Health Science Center at Houston, 77030 [Recruiting]
  • Richmond, Virginia, United States, VCU Health, 23298 [Recruiting]
Last updated 2021-08-18